Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.67 |
| ▸ | CA9 | Q16790 | 5/20 | 0.67 |
| ▸ | CA1 | P00915 | 4/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.59 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | HPGD | P15428 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | CASP1 | P29466 | 4/20 | 0.57 |
| ▸ | CASP7 | P55210 | 4/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.57 |
| ▸ | GLA | P06280 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2188796 | 1.00 | CA12 (0.67) | CA12CA9CA1CA2CA7 | |
| SCHEMBL1679606 | 1.00 | CA12 (0.67) | CA12CA9CA1CA2CA7 | |
| SCHEMBL1072470 | 1.00 | CA12 (0.67) | CA12CA9CA1CA2CA7 | |
| SCHEMBL15124782 | 1.00 | CA12 (0.67) | CA12CA9CA1CA2CA7 | |
| SCHEMBL8403748 | 1.00 | CA12 (0.67) | CA12CA9CA1CA2CA7 | |
| SCHEMBL165951 | 1.00 | CA12 (0.67) | CA12CA9CA1CA2CA7 | |
| SCHEMBL2778091 | 1.00 | CA12 (0.67) | CA12CA9CA1CA2CA7 | |
| SCHEMBL336407 | 1.00 | CA12 (0.67) | CA12CA9CA1CA2CA7 | |
| SCHEMBL4074640 | 0.99 | CA12 (0.65) | CA12CA9CA1CA2CA7 | |
| SCHEMBL7766916 | 0.99 | CA12 (0.65) | CA12CA9CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325206-A1 | Method for assaying the activity of lysosomal enzymes | GENZYME CORPORATION (US) | 2009-12-31 | — | — | US | claimed |
| US-20230175024-A1 | A METHOD OF PRODUCING AN ORGANIC ACID IN A MIXTURE OF MOLASSES AND CALCIUM HYDROXIDE | FF-FUTURE OY (FI) | 2023-06-08 | — | — | US | disclosed |
| EP-3231871-A1 | MEDICAL PREPARATIONS FOR THE TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY | Shire Human Genetic Therapies, Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2314699-B1 | MEDICAL PREPARATIONS FOR THE TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY | SHIRE HUMAN GENETIC THERAPIES (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2186902-B1 | Medical preparations for the treatment of alpha-galactosidase a deficiency | SHIRE HUMAN GENETIC THERAPIES (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20110280856-A1 | TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY | SELDEN RICHARD F (US) | 2011-11-17 | — | — | US | disclosed |
| EP-2314699-A1 | Medical preparations for the treatment of alpha-galactosidase A deficiency | Shire Human Genetic Therapies, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-2287319-A1 | Medical preparations for the treatment of alpha-galactosidase a deficiency | Shire Human Genetic Therapies, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| EP-2186902-A2 | Medical preparations for the treatment of alpha-galactosidase a deficiency | Shire Human Genetic Therapies, Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| EP-1163349-B1 | MEDICAL PREPARATIONS FOR THE TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY | SHIRE HUMAN GENETIC THERAPIES (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20040016021-A1 | Production of lysosomal enzymes in plants by transient expression | LARGE SCALE BIOLOGY CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20030113894-A1 | Therapy for kidney diseases; cardiovascular disorders | TRANSKARYOTIC THERAPIES, INC., A DELAWARE CORPORATION | 2003-06-19 | — | — | US | disclosed |
| US-20030106095-A1 | Production of lysosomal enzymes in plants by transient expression | KENTUCKY BIOPROCESSING, LLC | 2003-06-05 | — | — | US | disclosed |
| US-20030077806-A1 | Composition for use in the treatment of lysosomal storage defects | TRANSKARYOTIC THERAPIES, INC., A DELAWARE CORPORATION | 2003-04-24 | — | — | US | disclosed |
| US-6458574-B1 | HIGHLY PURIFIED ALPHA-GALACTOSE A GLYCOFORMS BY CHARGE ALTERATIONS BY INCREASING THE SIALIC ACID CONTENT AND/OR BY INCREASING THE PHOSPHORYLATION; HALF-LIFE; BIOAVAILABILITY; FABRY'S DISEASE; CARDIOVASCULAR DISORDERS | TRANSKARYOTIC THERAPIES, INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020088024-A1 | Production of lysosomal enzymes in plants by transient expression | KENTUCKY BIOPROCESSING, LLC | 2002-07-04 | — | — | US | disclosed |
| WO-2002008404-A2 | PRODUCTION OF LYSOSOMAL ENZYMES IN PLANTS BY TRANSIENT EXPRESSION | LARGE SCALE BIOLOGY CORPORATION (US) | 2002-01-31 | — | — | WO | disclosed |
| EP-1163349-A2 | MEDICAL PREPARATIONS FOR THE TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY | TRANSKARYOTIC THERAPIES, INC. (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000053730-A9 | MEDICAL PREPARATIONS FOR THE TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY | TRANSKARYOTIC THERAPIES INC (US) | 2001-10-11 | — | — | WO | disclosed |
| WO-2000053730-A2 | MEDICAL PREPARATIONS FOR THE TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY | TRANSKARYOTIC THERAPIES, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280856-A1 | TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY | GLA, GALC, GAA | CA12 709/4885CA9 831/4885CA1 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.